-
1
-
-
13644269309
-
Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia
-
Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
-
(2005)
Am. J. Respir Crit. Care Med.
, vol.171
, pp. 388-416
-
-
-
2
-
-
0032531113
-
Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients
-
Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-440.
-
(1998)
Ann. Intern. Med.
, vol.129
, pp. 433-440
-
-
Cook, D.J.1
Walter, S.D.2
Cook, R.J.3
-
3
-
-
34047261095
-
Estimating health care-associated infections and deaths in U. S. hospitals, 2002
-
Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U. S. hospitals, 2002. Public Health Rep 2007;122:160-166.
-
(2007)
Public Health Rep.
, vol.122
, pp. 160-166
-
-
Klevens, R.M.1
Edwards, J.R.2
Richards Jr., C.L.3
-
4
-
-
0346753421
-
National Nosocomial Infections Surveillance (NNIS)
-
National Nosocomial Infections Surveillance System, System Report, data summary from January 1992 through June 2003; issued August 2003
-
National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003; issued August 2003. Am J Infect Control 2003;31:481-498.
-
(2003)
Am. J. Infect. Control
, vol.31
, pp. 481-498
-
-
-
5
-
-
26444480583
-
Clinical and economic consequences of ventilator-associated pneumonia: A systematic review
-
Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med 2005;33:2184-2193.
-
(2005)
Crit. Care Med.
, vol.33
, pp. 2184-2193
-
-
Safdar, N.1
Dezfulian, C.2
Collard, H.R.3
-
6
-
-
0038662785
-
Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center
-
Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-1317.
-
(2003)
Crit. Care Med.
, vol.31
, pp. 1312-1317
-
-
Warren, D.K.1
Shukla, S.J.2
Olsen, M.A.3
-
8
-
-
9344239309
-
Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
-
ICU-acquired Pneumonia Study Group
-
Alvarez-Lerma F, ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996;22:387-394.
-
(1996)
Intensive Care Med.
, vol.22
, pp. 387-394
-
-
Alvarez-Lerma, F.1
-
9
-
-
0036304245
-
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia
-
Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-268.
-
(2002)
Chest
, vol.122
, pp. 262-268
-
-
Iregui, M.1
Ward, S.2
Sherman, G.3
-
10
-
-
77957608917
-
-
Unpublished data on file. Ortho-McNeil Janssen Scientific Affairs, Raritan, NJ
-
Unpublished data on file. Ortho-McNeil Janssen Scientific Affairs, Raritan, NJ.
-
-
-
-
11
-
-
41649099025
-
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study
-
Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008:36; 1089-1096.
-
(2008)
Crit. Care Med.
, vol.36
, pp. 1089-1096
-
-
Chastre, J.1
Wunderink, R.2
Prokocimer, P.3
-
12
-
-
77957580747
-
Susceptibility of Pseudomonas aeruginosa to doripenem and imipenem in the United States: 2006-2007 TRUST surveillance
-
Poster presentation at, Honolulu, HI, February 2-6
-
Brown N, Draghi DH, Yee YC, et al. Susceptibility of Pseudomonas aeruginosa to doripenem and imipenem in the United States: 2006-2007 TRUST surveillance. Poster presentation at the 37th Critical Care Congress. Honolulu, HI, February 2-6, 2008.
-
(2008)
The 37th Critical Care Congress
-
-
Brown, N.1
Draghi, D.H.2
Yee, Y.C.3
-
13
-
-
0029794708
-
Recommendations of the panel on cost-effectiveness in health and medicine
-
Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
-
(1996)
JAMA
, vol.276
, pp. 1253-1258
-
-
Weinstein, M.C.1
Siegel, J.E.2
Gold, M.R.3
-
14
-
-
0029863296
-
Ventilator-associated pneumonia due to Pseudomonas aeruginosa
-
Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-1029.
-
(1996)
Chest
, vol.109
, pp. 1019-1029
-
-
Brewer, S.C.1
Wunderink, R.G.2
Jones, C.B.3
Leeper, K.V.4
-
15
-
-
33749028483
-
Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes
-
Lautenbach E, Weiner MG, Nachamkin I, et al. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893-900.
-
(2006)
Infect. Control Hosp. Epidemiol
, vol.27
, pp. 893-900
-
-
Lautenbach, E.1
Weiner, M.G.2
Nachamkin, I.3
-
18
-
-
77957587068
-
-
Period Life Table, Available at, Accessed August 20, 2008
-
US Social Security Administration. Period Life Table, 2004. Available at http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed August 20, 2008.
-
(2004)
US Social Security Administration
-
-
-
19
-
-
1642451852
-
Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin
-
Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-143.
-
(2004)
Crit. Care Med.
, vol.32
, pp. 137-143
-
-
Shorr, A.F.1
Susla, G.M.2
Kollef, M.H.3
-
20
-
-
0031003777
-
Magnitude and duration of the effect of sepsis on survival
-
Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. JAMA 1997;277:1058-1063.
-
(1997)
JAMA
, vol.277
, pp. 1058-1063
-
-
Quartin, A.A.1
Schein, R.M.2
Kett, D.H.3
-
21
-
-
0034561810
-
Outcomes and costeffectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome
-
Hamel MB, Phillips RS, Davis RB, et al. Outcomes and costeffectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med 2000;109:614-620.
-
(2000)
Am. J. Med.
, vol.109
, pp. 614-620
-
-
Hamel, M.B.1
Phillips, R.S.2
Davis, R.B.3
-
22
-
-
84877495647
-
-
Consumer Price Index. Available at, Accessed August 20, 2008
-
US Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov. Accessed August 20, 2008.
-
US Bureau of Labor Statistics
-
-
-
23
-
-
84858006048
-
-
Available at, Accessed September 3, 2008
-
Institute for Healthcare Improvement. Available at http://www.ihi.org. Accessed September 3, 2008.
-
Institute for Healthcare Improvement
-
-
-
25
-
-
77957586218
-
-
U. S. Government, 527-23, 576. Available at, DOCID: fr30ap08-26. Accessed May 8, 2008
-
U. S. Government. Proposed Rules. Fed Reg 2008;73:23, 527-23, 576. Available at http://wais.access.gpo.gov [DOCID: fr30ap08-26]. Accessed May 8, 2008.
-
(2008)
Proposed Rules. Fed Reg
, vol.73
, pp. 23
-
-
-
26
-
-
3342905057
-
Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential
-
Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48:3086-3092.
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 3086-3092
-
-
Mushtaq, S.1
Ge, Y.2
Livermore, D.M.3
-
27
-
-
33744950954
-
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: The high potency of a new carbapenem doripenem
-
Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: The high potency of a new carbapenem doripenem. J Antibiot 2006;59:220-228.
-
(2006)
J. Antibiot
, vol.59
, pp. 220-228
-
-
Sakyo, S.1
Tomita, H.2
Tanimoto, K.3
-
28
-
-
70350397040
-
Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa
-
Shigemi A, Matsumoto K, Yaji K, et al. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2009;34:589-591.
-
(2009)
Int. J. Antimicrob. Agents
, vol.34
, pp. 589-591
-
-
Shigemi, A.1
Matsumoto, K.2
Yaji, K.3
-
29
-
-
0037253093
-
Costeffectiveness of drotrecofin alfa (activated) in the treatment of sepsis
-
Angus DC, Linde-Zwirble WT, Clermont G, et al. Costeffectiveness of drotrecofin alfa (activated) in the treatment of sepsis. Crit Care Med 2003;31:1-11.
-
(2003)
Crit. Care Med.
, vol.31
, pp. 1-11
-
-
Angus, D.C.1
Linde-Zwirble, W.T.2
Clermont, G.3
|